retatrutide glp-1 retatrutide 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide vs Semaglutide and Tirzepatide:

, The most recent published research (January 2025), a large nationwide case-time-control study using data in France, found no evidence that GLP-1 use increased short-term risk of suicide or suicide attempt in patients with obesity or history of psychiatric disorders

The typical starting dosage of Rybelsus is 3 mg once daily

Popular treatments approved by the FDA include Sales for Lillys GLP-1 treatments reached $40 billion in 2025, accounting for 62% of the companys annual revenue

Athletes are not immune to the messaging

For practical patient education, this means: do not let appetite suppression cause protein neglect spread protein across the day rather than eating most of it at dinner use convenient protein sources when appetite is low tailor targets to the persons age, activity, and body composition Examples include: eggs or egg whites Greek yogurt cottage cheese chicken or turkey fish lean beef tofu or tempeh protein shakes when needed 2

Permanent link to this press release: Copy Please set a link in the press area of your homepage to this press release on openPR